Saturday 17 October 2026
Export MIST’s income statement to Excel — free account
Milestone Pharmaceuticals Inc.
MIST Healthcare Biotechnology
Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023. In the quarter to June 2026, revenue fell 62.7%, EPS fell 5.00%, free cash flow fell 80.8% and total debt rose 7.19%, each against the same quarter a year earlier.
0.71
0.09
−11.25%
Follow MIST
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
35.09 | 24.85 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(8.18) | (9.66) | — | — | |
P/B ratio |
10.20 | 4.30 | — | — | |
Price to Tangible BV |
10.20 | 4.30 | — | — | |
EV/Sales |
14.05 | 4.65 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(1.21) | (0.57) | — | — | |
EV/FCF |
(1.21) | (0.56) | — | — | |
Quick Ratio |
7.85 | 8.94 | 7.70 | 7.91 | |
Current Ratio |
8.13 | 9.18 | 8.01 | 8.24 | |
Net Debt/EBITDA |
4.36 | 5.34 | 2.60 | 2.23 | |
Debt/Assets |
32.60% | 30.04% | 50.36% | 64.05% | |
Debt/Equity |
3.25 | 1.61 | 1.37 | 2.74 | |
Asset Turnover |
0.05 | 0.05 | 0.00 | 0.00 | |
Operating CF/Net income |
0.79 | 0.62 | 0.73 | 0.82 | |
Capex/Depreciation |
(0.46) | (0.80) | (8.32) | (0.08) | |
Interest Coverage |
(5.42) | (5.72) | (17.52) | (12.23) | |
Research and Development Expense of Revenue |
627.73% | 1,365.97% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
4,051.52% | 2,026.89% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
239.36% | 538.66% | 0.00% | 0.00% | |
Graham Net Nets |
0.09 | 0.22 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(51.49%) | (57.14%) | — | — | |
Free Cash Flow Yield |
(33.17%) | (33.21%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.12) | (0.15) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.12) | (0.16) | (0.10) | |
Cash per Share |
1.23 | 1.41 | 1.26 | 0.86 | |
Shareholders Equity per Share |
0.13 | 0.28 | 0.50 | 0.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.13 | 0.28 | 0.50 | 0.21 | |
Free Cash Flow |
(22.74) | (16.10) | (13.06) | (9.75) | |
Working Capital |
158.14 | 171.31 | 97.94 | 76.15 | |
Capital Expenditures |
(0.03) | (0.04) | (0.28) | 0.00 | |
Net Current Asset Value |
16.92 | 34.57 | 40.13 | 19.42 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.05 | 0.19 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
2.19 | 2.10 | 1.57 | 0.96 | |
Average Payables |
8.61 | 11.22 | 6.60 | 7.36 | |
Average Assets |
114.52 | 127.81 | 94.53 | 85.23 | |
Average Common Equity |
0.24 | 14.96 | 27.46 | 22.26 |
Columns are period end dates